MicroRNAs as Bile-Based Biomarkers in Pancreatic Cancer and Biliary Tract Cancers
Poster May 09, 2017
M. Mato Prado*1, A. E. Frampton*1,2, N. Funel3,4, E. Lopez-Jimenez1, L. Castellano1, P. Lawton1, L. L. Meijer5, G. Kazemier5, L. R. Jiao2, J. Stebbing*1, E. Giovannetti*4,6, J. Krell*1
Pancreatic cancer is one of the most lethal diseases in the world with 9,618 new cases and around 8,800 deaths in the UK. It is the fourth most common cause of cancer death in the UK (2014). The lack of efficient diagnostic techniques and limited treatment options leads to a late detection and poor survival rates (less than 1%)1.Therefore, further investigation is needed to improve the detection process and design specific molecular targeted treatments.
During last decade, a class of non-coding RNAs (microRNAs) are emerging as potential biomarkers and therapeutic targets for different cancers. In this study, the role of miRNAs has been assessed in a large cohort of pancreatic cancer.
Despite the developments in conventional PCR, the complexity of multiplex Real Time PCR is still limited due to the lack of sufficient detection channels. To achieve high-end multiplexing capacity on standard Real Time PCR machines, Anapa Biotech has developed the MeltPlex® technology (see box on right).READ MORE